UBS Asset Management and Reef Group have achieved planning consent on the revised masterplan of their £100+ million Elevate Quarter in Stevenage.
The scheme will provide 1.6 million sq ft of lab, office, and Good Manufacturing Practices (GMP) facilities, as well as two data centres. Furthermore, the car parking spaces have been designed to accommodate future repurposing, disassembly and reutilisation, thereby allowing the campus to adapt over time.
Stevenage is currently the largest cell and gene therapy cluster outside the United States. The town is home to GSK’s European headquarters for R&D, Cell & Gene Therapy Catapult as well as Stevenage Bioscience Catalyst.
Ewan Graham, partner and healthcare sector lead at Hawkins Brown, the project architects, said: “The revised planning consent for Elevate Quarter marks an important and forward‑looking evolution of the scheme. By integrating two major data centres alongside life sciences and GMP facilities, we’re creating a more resilient, future proofed ecosystem that reflects how innovation is actually happening today.
“This shift strengthens Stevenage’s position as a nationally significant hub for advanced technologies and science, while bringing forward much needed regeneration of a brownfield site.”
A range of consultancies were used including Savills (planning), Gardiner & Theobald (cost consultant), Exterior Architecture (landscape architect), Curtins (structural & civil engineering) and Paul Mew Associates (transport) among others.
Image: Hawkins Brown
© Eastern Echo (powered by ukpropertyforums.com).
This article and its contents are the intellectual property of UK Property Forums and may not be reproduced, distributed, or used in any form without prior written permission. The views expressed are those of the author(s) and do not constitute legal or professional advice.
